NY-WEBBING
5.4.2022 14:03:04 CEST | Business Wire | Press release
Webbing , a global MVNO (Mobile Virtual Network Operator) connectivity provider for enterprise mobility and IoT, today announced the immediate availability of WebbingCTRL , a fast and simple global-ready connectivity solution. WebbingCTRL is the only SIM in the world that can easily and remotely become any wireless carrier’s SIM, eliminating network provider lock-in and providing complete control over connectivity with zero-touch provisioning.
IoT connectivity can require substantial costs and time to orchestrate the implementation of network providers. Additionally, IoT use cases are rapidly changing, so organizations need a way to make future-proof decisions today in order to handle connectivity challenges on the horizon. Using the WebbingCTRL platform, organizations can easily add, remove, and swap the carrier for any number of IoT or enterprise deployments to another wireless carrier of their choice with which they have an eSIM subscription. There’s no need for carrier integration.
The IoT environment is accelerating, and connectivity solutions need to adapt to fast-moving deployments now and in the future. The WebbingCTRL eSIM delivers total flexibility to ensure devices have reliable connectivity, anywhere in the world. The ability to remotely provision devices without extra carrier integration or collaboration also vastly reduces time-consuming deployment cycles and could have a huge impact on the ability to scale.
The WebbingCTRL solution eSIM is device agnostic and comes in any form factor. As a result, businesses can gain complete control over connectivity for a wide array of use cases, including:
- Enterprise employee mobile connectivity: Enables organizations to provide seamless connectivity for employees as they cross national boundaries and enter areas where one carrier may have better coverage than another.
- Transportation and logistics : Enable IoT tracking devices to switch automatically from a private network in a warehouse to a public network when in transit.
- Mission-critical IoT: Prevent interruption to operations that depend on connectivity when one carrier’s coverage is down by switching automatically to another.
- Automotive: Connected vehicles need constant connectivity and they cannot always use a roaming carrier due to regional connectivity regulations. WebbingCTRL can automatically change carriers as vehicles cross into new coverage areas or national borders.
“With WebbingCTRL, companies can finally take complete control of their connectivity to ensure business continuity, take advantage of better pricing and coverage and avoid having to physically touch hundreds, even thousands of devices to change carriers,” said Noam Lando, co-founder and CEO at Webbing. “Companies can securely control all their devices’ connectivity, with the confidence to connect anywhere in the world, 24-7, both now and in the future.”
Because WebbingCTRL works independently of SM-DP and SM-SR infrastructure, the carrier change takes place almost immediately, and the eSIM will act just as if the SIM card had been physically changed to the new carrier. And WebbingCTRL is not limited to public networks but can also be used to manage connectivity to private networks.
Additionally, companies can set up business rules that will automatically change the carrier under specific conditions, such as location, country, loss of connectivity or even after a certain amount of time.
For more information about WebbingCTRL and ways to streamline your IoT deployment, contact sales@iamwebbing.com .
About Webbing
Webbing is a global data MVNO that delivers innovative enterprise grade, global connectivity and IoT services. Our secured network of 600+ mobile carriers across more than 200 countries, ensures superior data connectivity between businesses, people, and things wherever the device is located.
Since our foundation in 2010, we have been developing revolutionary SIM technology, powerful management platforms and a robust global network that revolutionize your data, making it relevant and actionable. Our leading-edge solutions deliver a streamlined, centralized, and scalable means of deploying and managing organizations' global fleet of devices. Our experts assist in every step of the device on boarding process to ensure you are set up to meet your organization’s connectivity needs. For more information, visit https://www.webbingsolutions.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220405005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
